We are live on
!
Find out more
TLP
Tri Locum Partners Portfolio holdings
AUM
$713M
1-Year Est. Return
68.92%
This Fund
S&P 500
This Quarter
Est. Return
+29.5%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$275M
AUM Growth
–
Cap. Flow
+$252M
Cap. Flow
% of AUM
91.48%
Top 10 Holdings %
Top 10 Hldgs %
61.92%
Holding
65
New
65
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$24M |
| 2 |
Baxter International
BAX
|
+$23.7M |
| 3 |
Medtronic
MDT
|
+$22.5M |
| 4 |
AbbVie
ABBV
|
+$18.6M |
| 5 |
WBA
Walgreens Boots Alliance
WBA
|
+$17.1M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.78% |
| 2 | Consumer Staples | 1.61% |
| 3 | Communication Services | 0.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Johnson & Johnson
JNJ
$609B
| $25.6M | 9.3% |
+162,633
| New | +$24M |
|
|
2
Baxter International
BAX
$11.7B
| $24M | 8.7% |
+298,721
| New | +$23.7M |
|
|
3
Medtronic
MDT
$106B
| $23.9M | 8.68% |
+204,138
| New | +$22.5M |
|
|
4
AbbVie
ABBV
$450B
| $20.7M | 7.52% |
+193,223
| New | +$18.6M |
|
5
Viatris
VTRS
$20.1B
| $19.6M | 7.12% |
+1,046,794
| New | +$17.1M |
|
|
WBA
6
DELISTED
Walgreens Boots Alliance
WBA
| $17.6M | 6.39% |
+441,324
| New | +$17.1M |
|
7
Labcorp
LH
$23.2B
| $11M | 4% |
+62,978
| New | +$10.9M |
|
|
CCXI
8
DELISTED
ChemoCentryx, Inc.
CCXI
| $10.3M | 3.73% |
+166,077
| New | +$9.51M |
|
9
Eli Lilly
LLY
$1.05T
| $9.37M | 3.4% |
+55,521
| New | +$8.29M |
|
10
Zai Lab
ZLAB
$2.28B
| $8.42M | 3.06% |
+62,235
| New | +$6.33M |
|
|
BPMC
11
DELISTED
Blueprint Medicines
BPMC
| $8.29M | 3.01% |
+73,906
| New | +$7.79M |
|
12
Elevance Health
ELV
$80.9B
| $7.5M | 2.73% |
+23,374
| New | +$7.17M |
|
|
MRSN
13
DELISTED
Mersana Therapeutics
MRSN
| $7.24M | 2.63% |
+10,879
| New | +$6.05M |
|
|
APLS
14
DELISTED
Apellis Pharmaceuticals
APLS
| $6.95M | 2.52% |
+121,409
| New | +$5.14M |
|
15
Incyte
INCY
$23.4B
| $5.86M | 2.13% |
+67,384
| New | +$5.83M |
|
16
Protagonist Therapeutics
PTGX
$9.06B
| $5.23M | 1.9% |
+259,283
| New | +$5.58M |
|
17
Regeneron Pharmaceuticals
REGN
$70.9B
| $5.04M | 1.83% |
+10,423
| New | +$5.63M |
|
|
GWPH
18
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $4.63M | 1.68% |
+40,159
| New | +$4.5M |
|
|
TRIL
19
DELISTED
Trillium Therapeutics Inc.
TRIL
| $4.37M | 1.59% |
+296,838
| New | +$4.28M |
|
20
Arrowhead Research
ARWR
$10.5B
| $4.3M | 1.56% |
+56,003
| New | +$3.58M |
|
21
TG Therapeutics
TGTX
$8.4B
| $3.64M | 1.32% |
+69,932
| New | +$2.36M |
|
22
ALX Oncology
ALXO
$283M
| $3.38M | 1.23% |
+39,226
| New | +$2.36M |
|
|
AXNX
23
DELISTED
Axonics, Inc. Common Stock
AXNX
| $3.21M | 1.17% |
+64,378
| New | +$3.02M |
|
|
SNCE
24
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| $3.2M | 1.16% |
+15,000
| New | +$3.12M |
|
25
Intellia Therapeutics
NTLA
$1.59B
| $3.07M | 1.11% |
+56,402
| New | +$2.05M |
|
Similar funds
DCM
AMPWP
DCM
IWP
LS
PCS
ACGDR
GEA
Tri Locum Partners's Q4 2020 Portfolio in Review
Q4 2020 is the first quarter with a 13F filing on record for Tri Locum Partners, which disclosed 65 positions worth $275M. Its ten largest holdings account for 62% of the portfolio.
Its largest position is Johnson & Johnson: 162,633 shares worth $25.6M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, followed by Consumer Staples and Communication Services.
- Tri Locum Partners's largest Q4 2020 buy was Johnson & Johnson: 162,633 shares worth $25.6M.
- Tri Locum Partners's ten largest holdings make up 62% of its $275M portfolio in Q4 2020.
- Tri Locum Partners disclosed 65 positions in Q4 2020, its first 13F filing on record.
Based on Tri Locum Partners's 13F filing for Q4 2020, filed 16 Feb 2021.